



(11) **EP 1 909 837 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
02.06.2010 Bulletin 2010/22

(45) Date of publication and mention
of the grant of the patent:
21.04.2010 Bulletin 2010/16

(21) Application number: **06764231.4**

(22) Date of filing: **19.07.2006**

(51) Int Cl.:
A61K 45/06 ^(2006.01) **A61K 31/553** ^(2006.01)
A61K 31/506 ^(2006.01)

(86) International application number:
PCT/EP2006/064431

(87) International publication number:
WO 2007/010014 (25.01.2007 Gazette 2007/04)

(54) **COMPOSITIONS FOR TREATMENT OF SYSTEMIC MASTOCYTOSIS**

ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON SYSTEMISCHER MASTOCYTOSE
COMPOSITIONS POUR LE TRAITEMENT DE MASTOCYTOSE SYSTEMIQUE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR**

(30) Priority: **20.07.2005 US 701098 P**

(43) Date of publication of application:
16.04.2008 Bulletin 2008/16

(73) Proprietor: **Novartis AG**
4056 Basel (CH)

(72) Inventor: **Valent Peter**
1097 Vienna (AT)

(74) Representative: **Crawley, Patrick Edward et al**
Novartis AG
Geistiges Eigentum Konzern
Patent- und Markenabteilung CH
Postfach
4002 Basel (CH)

(56) References cited:
WO-A-2005/027971 WO-A-2005/049032
WO-A-2006/135790

- **KLUIN-NELEMANS HANNEKE C ET AL:**
"Cladribine therapy for systemic mastocytosis."
BLOOD, vol. 102, no. 13, 15 December 2003
(2003-12-15), pages 4270-4276, XP007901879
ISSN: 0006-4971
- **SHAH NEIL P ET AL:** "BMS-354825 IS A SRC/ABL
INHIBITOR WITH HIGH NANOMOLAR ACTIVITY
AGAINST THE KIT D816V MUTATION, WHICH
DRIVES SYSTEMIC MASTOCYTOSIS AND IS
IMATINIB-RESISTANT" **BLOOD**,
W.B.SAUNDERS COMPANY, ORLANDO, FL, US,
vol. 104, no. 11, PART 1, November 2004
(2004-11), page 228A, XP008069869 ISSN:
0006-4971
- **GLEIXNER K V ET AL:** "PKC412 inhibits in vitro
growth of neoplastic human mast cells
expressing the D816V-mutated variant of KIT:
comparison with AMN107, imatinib, and
cladribine (2CdA) and evaluation of cooperative
drug effects" **BLOOD**, W.B.SAUNDERS
COMPANY, ORLANDO, FL, US, vol. 107, no. 2, 27
September 2005 (2005-09-27), pages 752-759,
XP002399639 ISSN: 0006-4971

EP 1 909 837 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- **PARDANANI ET AL: "Pathogenesis, clinical features, and treatment advances in mastocytosis" BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, BAILLIÈRE TINDALL, vol. 19, no. 3, September 2006 (2006-09), pages 595-615, XP005492734 ISSN: 1521-6926**
- **BARBIE D A ET AL: "Systemic mastocytosis: Current classification and novel therapeutic options" CLINICAL ADVANCES IN HEMATOLOGY AND ONCOLOGY 2006 UNITED STATES, vol. 4, no. 10, 2006, pages 768-775, XP009080859 ISSN: 1543-0790**
- **PÉREZ-PÉREZ MARÍA-JESÚS ET AL: "MITOCHONDRIAL THYMIDINE KINASE INHIBITORS" CURRENT TOPICS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, vol. 5, no. 13, 2005, pages 1205-1219, XP009078740 ISSN: 1568-0266**
- **CHALANDON Y ET AL: "Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies" HAEMATOLOGICA 2005 ITALY, vol. 90, no. 7, 2005, pages 949-968, XP002425520 ISSN: 0390-6078 cited in the application**